Market Analysis and Insights: Global Bladder Cancer Therapeutics and Diagnostics Market
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
The global Bladder Cancer Therapeutics and Diagnostics market size is projected to reach US$ 710.7 million by 2028, from US$ 433 million in 2021, at a CAGR of 6.9% during 2022-2028.
Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bladder Cancer Therapeutics and Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bladder Cancer Therapeutics and Diagnostics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bladder Cancer Therapeutics and Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bladder Cancer Therapeutics and Diagnostics market.
Global Bladder Cancer Therapeutics and Diagnostics Scope and Market Size
Bladder Cancer Therapeutics and Diagnostics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Bladder Cancer Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Chemotherapy
Immunotherapy
Radiation Therapy
Others
Segment by Application
Hospitals
Oncology Treatment Centers
Ambulatory Surgery Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
GlaxoSmithKline
Merck
Novartis
Bristol-Myers Squibb
Eli Lilly
Roche
Sanofi
AstraZeneca
Celgene Corporation